Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03012165 · ClinicalTrials.gov registry record · Phase 2
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
A Phase 2 study, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 154
- Enrollment target
NCT03012165: Completed Phase 2 study, sponsored by Aldeyra Therapeutics.
NCT03012165 is a Phase 2 study that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 154 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (16% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03012165, a Phase 2 study, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 154 participants
- Enrollment target
Study Summary
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2b Evaluation of the Onset and Duration of ADX-102 Ophthalmic Drops (0.5% and 0.1%) Compared to Vehicle of ADX-102 Ophthalmic Drops in the Conjunctival Allergen Challenge (Ora-CAC®) Model of Acute Allergic Conjunctivitis.
Primary Outcome
Ocular itching using the Ora Calibra® Conjunctival Allergen Challenge Ocular Itching Scale (0 = least, 4= most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.
Interventions
- DRUG ADX-102 Ophthalmic Drops (0.5%)
- DRUG ADX-102 Ophthalmic Drops (0.1%)
- DRUG Vehicle of ADX-102 Ophthalmic Drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2016-12 |
| Est. Completion | 2017-05 |
| Phase | Phase 2 |
What the finished NCT03012165 record still lists
NCT03012165 is an interventional study that assigns participants to a tested intervention. The registered 154 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (16% higher).
The record links to 0 conditions, and to 3 interventions - of which ADX-102 Ophthalmic Drops (0.5%) is the first listed.
NCT03012165 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03012165 about?
NCT03012165 is a clinical study titled "A Study of ADX-102 in Subjects With Allergic Conjunctivitis". A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2b Evaluation of the Onset and Duration of ADX-102 Ophthalmic Drops (0.5% and 0.1%) Compared to Vehicle of ADX-102 Ophthalmic Drops in the Conjunctival Allergen Challenge (Ora-CAC®) Model of Acute Allergic Conjunctivitis.
What is the current status of trial NCT03012165?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2016-12. Estimated completion is 2017-05.
What interventions are being tested in trial NCT03012165?
The interventions under investigation include: ADX-102 Ophthalmic Drops (0.5%) (DRUG), ADX-102 Ophthalmic Drops (0.1%) (DRUG), Vehicle of ADX-102 Ophthalmic Drops (DRUG).
Who is sponsoring clinical trial NCT03012165?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03012165's enrollment target sits among peer trials
154 448th of 2000 higher than 1,552 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04300998 · 154 participants
Study of CAR-T Therapy in Older Patients
- NCT04597372 · 154 participants · Phase 2
Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery
- NCT05294042 · 154 participants · NA
Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities
- NCT05512390 · 154 participants · Phase 1
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia